Chief Operating Officer, Oryn Therapeutics
Bioinspired Orynotides for Inflammatory and Infectious Diseases
ORYN is developing macrocyclic peptide therapeutics. Orynotides are engineered theta-defensin analogs under development for autoimmune, inflammatory, and infectious diseases. This presentation will provide an overview of the preclinical and clinical stages of development for each of these applications.
Dr. Selsted’s laboratory is focused on the study of defensins in innate immunity and inflammation. Over his career, he and his colleagues identified three genetically related mammalian subfamilies (α, β, and θ) of defensins. θ-defensins are uniquely produced in Old World monkeys and are the only known backbone cyclized peptides in animals. Selsted’s team showed that θ-defensins have remarkable immunoregulatory properties and a lead compound has advanced to the clinic as first-in-class drug for rheumatoid arthritis. Other theta-defensin analogs are under development as treatments for inflammatory bowel disease, antibiotic resistant “super bug” infections, and as cancer therapeutics.